Enhanced butyrylcholinesterase activity may be the common link in triggering low-grade systemic inflammation and decrease in cognitive function in diabetes mellitus and Alzheimer's disease

Current Nutrition and Food Science

Volumn 4, Issue 3, 2008, Pages 213-216

  Rao, Allam A ^a   Reddy, C Siva ^b   Sridhar, G R ^c   Annapurna, A ^b   Hanuman, T ^d   Prameela, M ^a   Suresh, K ^a   Prasannalaxmi, S ^b   Das, Undurti N ^e  

^a ANDHRA UNIVERSITY   (India)

^b ANDHRA UNIVERSITY   (India)

^c Endocrine and Diabetes Centre   (India)

^d ACHARYA NAGARJUNA UNIVERSITY   (India)

^e UND LIFE SCIENCES   (United States)

Author keywords

Acetylcholine; Alzheimer's disease; Anti oxidants; Butyrylcholinesterase; Cognitive function; Diabetes mellitus; Hyperglycemia; Hyperlipidemia; Inflammation; Lipid peroxidation

Indexed keywords

ACETYLCHOLINE; CHOLINESTERASE; LIPID PEROXIDE; SUPEROXIDE DISMUTASE;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; COGNITIVE DEFECT; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; DYSLIPIDEMIA; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; FEMALE; INFLAMMATION; MALE; MAZE TEST; NONHUMAN; PRIORITY JOURNAL; RAT; REVIEW; RISK FACTOR; STREPTOZOCIN DIABETES; TISSUE LEVEL;

ANIMALIA;

EID: 55249099305     PISSN: 15734013     EISSN: None     Source Type: Journal    
DOI: 10.2174/157340108785133310     Document Type: Review

References (27)

1. Sridhar GR, Nirmala G, Appa Rao Allam, et al. Serum butyrylcholinesterase in type 2 diabetes mellitus: a biochemical and bioinformatics approach. Lipids Health Dis 2005; 4: 18.
2. Sridhar GR, Hanuman T, Appa Rao Allam, Suresh Babu C, Siva Prasad A, Divakar Ch. Alzheimer's disease and Type 2 diabetes mellitus: the cholinesterase connection? Lipids Health Dis 2006; 5: 28.
3. Rao AA, Sridhar GR, Das UN. Elevated butyrylcholinesterase and acetylcholinesterase may predict the development of type 2 diabetes mellitus and Alzheimer's disease. Med Hypotheses, in press.
4. Das UN. Clinical laboratory tools to diagnose inflammation. Adv Clin Chem 2006; 41: 189-229.
5. Das UN. Is metabolic syndrome X an inflammatory condition? Exp Biol Med 2002; 227: 989-997.
6. Ford ES. The metabolic syndrome and C-reactive protein, fibronogen, and leukocyte count: findings from the Third National Health and Nutrition Examination Survey. Atherosclerosis 2003; 168: 351-358.
7. Mohan IK, Das UN. Oxidant stress, anti-oxidants and nitric oxide in noninsulin dependent diabetes mellitus. Med Sci Res 1997; 25: 55-57.
8. Cacabelos R, Barquero M, Garcia P. Alvaez XA, Varela de Seijas E. Cerebrospinal fluid interleukun-1 beta (IL-1 beta) in Alzheimer's disease and neurological disorders. Methods Find Exp Clin Pharmacol 1991; 13: 455-458.
9. Fillit H, Ding WH, Buee L, et al. Elevated circulating tumor necrosis factor levels in Alzheimer's disease. Neurosci Lett 1991; 129: 318-320.
10. Greig NH, Utsuki T, Ingram DK, et al. Selective butyrylcholinesterase inhibition elevates brain acetylcholine, augments learning and lowers Alzheimer's β-amyloid peptide in rodent Proc Natl Acad Sci USA 2005; 102: 17213-17218.
11. Abbott CA, Mackness MI, Kumar S, et al. Relationship between serum butyrylcholinesterase activity, hypertriglyceridaemia and insulin sensitivity in diabetes mellitus. Clin Sci (Lond) 1993; 85: 77-81.
12. Borovikova LV, Ivanova S, Zhang M, et al. Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin. Nature 2000; 405: 458-462.
13. Das UN. Is metabolic syndrome X a disorder of the brain with the initiation of low-grade systemic inflammatory events during the perinatal period? J Nutr Biochem, in press.
14. Yagi K. A simple fluorometric assay for lipoperoxide in blood plasma. Biochem Med 1976; 15: 212-216.
15. Kakkar P, Das B, Viswanathan PN. A modified spectrophotometric assay of superoxide dismutase. J Biochem Biophys 1984; 21: 130-12.
16. Diamant S, Podoly E, Friedler A, Ligumsky H, Livnah O, Soreq H. Butyrylcholinesterase attenuates amyloid fibril formation in vitro. Proc Natl Acad Sci USA 2006; 103: 8628-8633.
17. Das UN. Acetylcholinesterase and butyrylcholinesterase as possible markers of low-grade systemic inflammation. Med Sci Monit 2007; 13: RA 214-RA 221.
18. Dave KR, Katyare SS. Effect of alloxan-unduced diabetes on serum and cardiac butyrylcholinesterase in the rat. J Endocrinol 2002; 175: 241-245.
19. Patel BN, Mackness MI, Harty DW, Arrol S, Boot-Handford RP, Durrington PN. Serum esterase activities and hyperlipidaemia in the streptozotocin-diabetic rat Biochim Biophys Acta 1990; 1035: 113-116.
20. Van Lith HA, Beynen AC. Dietary cholesterol lowers the activity of butyrylcholinesterase (EC 3.1.1.8), but elevates that of esterase-1 (EC 3.1.1.1) in plasma of rats. Br J Nutr 1993; 70: 721-726.
21. Van Lith HA, Herman S, Zhang X, Van Der Palen JG, Van Zuthen LF, Beynen AC. Influence of dietary fats on butyrylcholinesterase and esterase-1 (ES-1) activity in plasma of rats. Lipids 1990; 25: 779-786.
22. Suresh Y, Das UN. Long-chain polyunsaturated fatty acids and chemically-induced diabetes mellitus: effect of ω-6 fatty acids. Nutrition 2003; 19: 93-114.
23. Mazzanti L, Faloia E, Rabini RA, et al. Diabetes mellitus induces red blood cell plasma membrane alterations possibly affecting the aging process. Clin Biochem 1992; 25: 41-46.
24. Schallreuter KU, Gibbons NC, Zothner C, Elwary SM, Rokos H, Wood JM. Butyrylcholinesterase is present in the human epidermis and is regulated by H2O2: more evidence for oxidative stress in vitiligo. Biochem Biophys Res Commun 2006; 349: 931-938.
25. Tsakiris S, Schupis KH, Papaconstantinou ED, Tsakiris T, Tjamouranis I, Giannoulia-Karantana A. Erythrocyte membrane acetylcholinesterase activity in subjects with MTHFR 677-T genotype. Clin Chem Lab Med 2006; 44: 23-27.
26. Stefanello FM, Franzon R, Tagliari B, Wannmacher C, Wajiner M, Wyse AT. Reduction of butyrylcholinesterase activity in rat serum subjected to hyperhomocysteinemia Metab Brain Dis 2005; 20: 97-103.
27. Das UN. Folic acid says NO to vascular diseases. Nutrition 2003; 19: 686-692.